P-40 Outcome of hepatitis C patients treated with sofosbuvir/ daclatasvir in the Hepatitis Clinic at Georgetown Public Hospital Corporation
Author(s):
ESW Hatim, C Thom-Fernandes
Year of Presentation:
2025
Objective: To determine the demographics of patients
infected with hepatitis C enrolled in the clinic and their
response to treatment using direct-acting antiviral agents.
Methods: A retrospective chart review was conducted of all patients enrolled in the hepatitis C clinic from September 2022 – September 2023 . Relevant data needed to complete the research were extracted from patients’ charts, entered into a specially designed, protected Microsoft Office Excel spreadsheet and analyzed to meet the objectives outlined above.
Results: Forty-eight patients had a positive Hepatitis C antibody and viral load, 58% being males and 42% being females with a mean age of 52.8. Geographically, 37.6% of the patients were from region 2, while 37.5% from region 4. Treatment was initiated on forty-two patients while six patients will be initiated at the next visit. Twenty-nine patients completed treatment at the end of the study period, 11 were still on treatment while two defaulted. Twenty of the twenty-nine patients who completed treatment had a sustained virologic response 12 weeks after completing treatment while five are pending to be done at the end of the study period representing 83% sustained virologic response of the twenty-four patients who completed treatment and had post viral load testing done.
Conclusion: It is concluded that the treatment regimen is effective and tolerable at treating chronic Hepatitis C infection. This research serves to provide data for prospective studies on Hepatitis C in Guyana and the Caribbean in keeping with disease elimination objectives.